Announced details
Research involving cancer diagnosis using liquid biopsy, selection of therapeutic drugs, treatment response and recurrence monitoring
Track record of using this panel analysis in clinical trials in the United States (specific figures: Not disclosed)
Illumina K.K. will host the webinar, and our consolidated subsidiary CPM will introduce the service as a contract analysis company operating in Japan. Capital and personnel relationships: Not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Webinar hosted by Illumina K.K.; CPM website
| Item | Details |
|---|---|
| Names of Products / Services Covered | TruSight™ Oncology 500 (TSO500) ctDNA, Liquid biopsy contract analysis service |
| Counterparty | Illumina K.K. |
| Relationship with the Company | Illumina K.K. will host the webinar, and our consolidated subsidiary CPM will introduce the service as a contract analysis company operating in Japan. Capital and personnel relationships: Not disclosed. |
| Launch date | 20 August 2026 (scheduled webinar date) |
| Applicable area | Research involving cancer diagnosis using liquid biopsy, selection of therapeutic drugs, treatment response and recurrence monitoring |
| Usage history | Track record of using this panel analysis in clinical trials in the United States (specific figures: Not disclosed) |
| Source | Webinar hosted by Illumina K.K.; CPM website |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This panel analysis is expected to be used in a broad range of research, including cancer diagnosis using liquid biopsy, selection of therapeutic drugs, treatment response and recurrence monitoring.